EGF Induces Migration Independent of EMT or Invasion in A549 Lung Adenocarcinoma Cells.

EGF TGFβ cell migration epithelial to mesenchymal transition lung cancer

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2021
Historique:
received: 27 11 2020
accepted: 16 02 2021
entrez: 29 3 2021
pubmed: 30 3 2021
medline: 30 3 2021
Statut: epublish

Résumé

Tumors and the tumor microenvironment produce multiple growth factors that influence cancer cell behavior via various signal transduction pathways. Growth factors, like transforming growth factor β (TGFβ) and epidermal growth factor (EGF), have been shown to induce proliferation, migration, and invasion in different cell models. Both factors are frequently overexpressed in cancer and will often act in combination. Although both factors are being used as rational targets in clinical oncology, the similarities and differences of their contributions to cancer cell migration and invasion are not fully understood. Here we compared the impact of treating A549 lung adenocarcinoma cells with TGFβ, EGF, and both in combination by applying videomicroscopy, functional assays, immunoblotting, real-time PCR, and proteomics. Treatment with both factors stimulated A549 migration to a similar extent, but with different kinetics. The combination had an additive effect. EGF-induced migration depended on activation of the mitogen-activated protein kinase (MAPK) pathway. However, this pathway was dispensable for TGFβ-induced migration, despite a strong activation of this pathway by TGFβ. Proteome analysis (data are available via ProteomeXchange with identifier PXD023024) revealed an overlap in expression patterns of migration-related proteins and associated gene ontology (GO) terms by TGFβ and EGF. Further, only TGFβ induced the expression of epithelial to mesenchymal transition (EMT)-related proteins like matrix metalloproteinase 2 (MMP2). EGF, in contrast, made no major contribution to EMT marker expression on either the protein or the transcript level. In line with these expression patterns, TGFβ treatment significantly increased the invasive capacity of A549 cells, while EGF treatment did not. Moreover, the addition of EGF failed to enhance TGFβ-induced invasion. Overall, these data suggest that TGFβ and EGF can partly compensate for each other for stimulation of cell migration, but abrogation of TGFβ signaling may be more suitable to suppress cell invasion.

Identifiants

pubmed: 33777943
doi: 10.3389/fcell.2021.634371
pmc: PMC7994520
doi:

Types de publication

Journal Article

Langues

eng

Pagination

634371

Informations de copyright

Copyright © 2021 Schelch, Vogel, Schneller, Brankovic, Mohr, Mayer, Slany, Gerner and Grusch.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
pubmed: 11252954
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 27920038
Proc Natl Acad Sci U S A. 2012 May 15;109(20):7776-81
pubmed: 22547830
Int J Biochem Cell Biol. 2017 Sep;90:103-113
pubmed: 28778674
Differentiation. 2007 Nov;75(9):770-87
pubmed: 17999740
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Am J Physiol Renal Physiol. 2006 May;290(5):F1202-12
pubmed: 16368739
J Exp Clin Cancer Res. 2016 Jan 12;35:6
pubmed: 26754630
J Thorac Oncol. 2013 Mar;8(3):259-69
pubmed: 23334091
Cancer Biol Ther. 2019;20(7):956-966
pubmed: 31062668
Nature. 1985 Jan 10-18;313(5998):144-7
pubmed: 2981413
N Engl J Med. 2008 Dec 25;359(26):2814-23
pubmed: 19109576
Front Oncol. 2019 Oct 11;9:1044
pubmed: 31681582
Oncogene. 1999 Apr 1;18(13):2281-90
pubmed: 10327074
Mol Oncol. 2018 Jan;12(1):58-73
pubmed: 29094504
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
Cell Death Differ. 2015 Feb;22(2):336-50
pubmed: 25301070
Front Cell Dev Biol. 2020 Oct 29;8:571677
pubmed: 33195205
Eur Phys J Plus. 2016 Jan;131(1):
pubmed: 31367506
Mol Cancer Ther. 2012 Nov;11(11):2429-39
pubmed: 22927667
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Nat Rev Cancer. 2003 May;3(5):362-74
pubmed: 12724734
Cancer Res. 2014 May 15;74(10):2869-81
pubmed: 24686166
Int J Cancer. 1996 Jul 17;67(2):275-82
pubmed: 8760599
Nat Rev Mol Cell Biol. 2007 Dec;8(12):970-82
pubmed: 18000526
Cardiovasc Intervent Radiol. 2019 Sep;42(9):1213-1220
pubmed: 31270570
J Proteome Res. 2014 Jun 6;13(6):2874-86
pubmed: 24766643
Mol Cell Biol. 2015 Jan;35(1):88-100
pubmed: 25332240
Respir Res. 2005 Jun 09;6:56
pubmed: 15946381
Nat Protoc. 2014 Aug;9(8):1931-43
pubmed: 25033209
Trends Pharmacol Sci. 2019 Dec;40(12):941-955
pubmed: 31706618
Oncogene. 2008 Apr 17;27(18):2626-34
pubmed: 17982486
Front Oncol. 2018 Apr 30;8:133
pubmed: 29761075
Oncoimmunology. 2016 Dec 7;6(1):e1257453
pubmed: 28197376
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Immunol Lett. 2020 Mar;219:15-26
pubmed: 31904392
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Int J Oncol. 2016 Aug;49(2):700-8
pubmed: 27279345
Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72
pubmed: 25188816
BMC Bioinformatics. 2012;13 Suppl 16:S12
pubmed: 23176165
Cell Signal. 2006 Dec;18(12):2089-97
pubmed: 16815674
PLoS One. 2015 Sep 28;10(9):e0139074
pubmed: 26413866
Curr Cancer Drug Targets. 2010 Dec;10(8):849-57
pubmed: 20718708
Front Oncol. 2019 Mar 11;9:131
pubmed: 30915272
Carcinogenesis. 2018 Apr 5;39(4):534-545
pubmed: 29635378
Electrophoresis. 2014 May;35(10):1428-38
pubmed: 24644141
Am J Cancer Res. 2017 Feb 01;7(2):187-202
pubmed: 28337370
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Oncotarget. 2017 Sep 16;8(59):99801-99815
pubmed: 29245941
Cancer Metastasis Rev. 2020 Dec;39(4):1051-1065
pubmed: 32648136
Oncol Rep. 2015 Jul;34(1):87-94
pubmed: 25955797
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Sci Transl Med. 2018 Jun 20;10(446):
pubmed: 29925635
Cell Death Dis. 2018 Sep 24;9(10):976
pubmed: 30250119
Mol Cell Proteomics. 2017 Jan;16(1):86-99
pubmed: 27879288
J Korean Med Sci. 2007 Oct;22(5):898-904
pubmed: 17982242
Mol Cell Proteomics. 2016 Jun;15(6):1982-97
pubmed: 27025457
Cancers (Basel). 2020 May 28;12(6):
pubmed: 32481658
Clin Transl Med. 2015 Feb 26;4:6
pubmed: 25852822
J Cell Sci. 2015 Nov 1;128(21):3898-909
pubmed: 26359300
Cancer Metastasis Rev. 2020 Dec;39(4):1159-1177
pubmed: 32548736
Cancer Res. 2015 May 1;75(9):1789-800
pubmed: 25744723

Auteurs

Karin Schelch (K)

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Lisa Vogel (L)

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Anja Schneller (A)

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Jelena Brankovic (J)

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Thomas Mohr (T)

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Rupert L Mayer (RL)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.

Astrid Slany (A)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.

Christopher Gerner (C)

Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.

Michael Grusch (M)

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Classifications MeSH